Osteotech's Grafton DBM (demineralised bone matrix) products
This article was originally published in Clinica
Executive Summary
Osteotech has received US FDA 510(k) clearance for most of its family of Grafton demineralised bone matrix (DBM) products for use as a bone graft extender, bone graft substitute and bone void filler in orthopaedic indications. Covered in the firm's 510(k) application are its Grafton DBM Gel, Putty, Flex, Matrix, Crunch and Orthoblend. The FDA previously cleared the firm's Grafton Plus DBM paste for use in dental and orthopaedic procedures and its private label Viagraf DBM paste for orthopaedic procedures. "We believe Grafton DBM is the only DBM product on the market to receive clearance for all of these indications and-the only DBM product to be cleared as a bone graft substitute," said Sam Owusu-Akyaw, the Eatontown, New Jersey firm's president and CEO.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.